studies

Extensive stage SCLC (Es-SCLC), durvalumab plus etoposide and platin vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCASPIAN (D ; all population), 2019 0.73 [0.59; 0.91] 0.73[0.59; 0.91]CASPIAN (D ; all population), 201910%537NAnot evaluable deaths (OS) (extension)detailed resultsCASPIAN (D ; all population), 2019 0.75 [0.62; 0.91] 0.75[0.62; 0.91]CASPIAN (D ; all population), 201910%537NAnot evaluable PFS (extension)detailed resultsCASPIAN (D ; all population), 2019 0.80 [0.66; 0.96] 0.80[0.66; 0.96]CASPIAN (D ; all population), 201910%537NAnot evaluable progression or deaths (PFS)detailed resultsCASPIAN (D ; all population), 2019 0.78 [0.65; 0.94] 0.78[0.65; 0.94]CASPIAN (D ; all population), 201910%537NAnot evaluable objective responses (ORR)detailed resultsCASPIAN (D ; all population), 2019 1.64 [1.11; 2.43] 1.64[1.11; 2.43]CASPIAN (D ; all population), 201910%537NAnot evaluable AE (any grade)detailed resultsCASPIAN (D ; all population), 2019 1.61 [0.52; 4.99] 1.61[0.52; 4.99]CASPIAN (D ; all population), 201910%531NAnot evaluable AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.96 [0.68; 1.37] 0.96[0.68; 1.37]CASPIAN (D ; all population), 201910%531NAnot evaluable AE leading to death (grade 5)detailed resultsCASPIAN (D ; all population), 2019 0.86 [0.40; 1.85] 0.86[0.40; 1.85]CASPIAN (D ; all population), 201910%531NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.56; 1.80] 1.00[0.56; 1.80]CASPIAN (D ; all population), 201910%531NAnot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.35; 2.90] 1.00[0.35; 2.90]CASPIAN (D ; all population), 201910%531NAnot evaluable SAE (any grade)detailed resultsCASPIAN (D ; all population), 2019 0.79 [0.55; 1.14] 0.79[0.55; 1.14]CASPIAN (D ; all population), 201910%531NAnot evaluable SAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.77 [0.51; 1.15] 0.77[0.51; 1.15]CASPIAN (D ; all population), 201910%531NAnot evaluable STRAE (any grade)detailed resultsCASPIAN (D ; all population), 2019 0.66 [0.41; 1.05] 0.66[0.41; 1.05]CASPIAN (D ; all population), 201910%531NAnot evaluable STRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.51 [0.30; 0.86] 0.51[0.30; 0.86]CASPIAN (D ; all population), 201910%531NAnot evaluable TRAE (any grade)detailed resultsCASPIAN (D ; all population), 2019 0.92 [0.52; 1.61] 0.92[0.52; 1.61]CASPIAN (D ; all population), 201910%531NAnot evaluable TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.78 [0.55; 1.10] 0.78[0.55; 1.10]CASPIAN (D ; all population), 201910%531NAnot evaluable TRAE leading to death (grade 5)detailed resultsCASPIAN (D ; all population), 2019 2.54 [0.49; 13.20] 2.54[0.49; 13.20]CASPIAN (D ; all population), 201910%531NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCASPIAN (D ; all population), 2019 1.17 [0.54; 2.50] 1.17[0.54; 2.50]CASPIAN (D ; all population), 201910%531NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.75 [0.17; 3.38] 0.75[0.17; 3.38]CASPIAN (D ; all population), 201910%531NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.51 [0.25; 9.12] 1.51[0.25; 9.12]CASPIAN (D ; all population), 201910%531NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.52 [0.29; 0.91] 0.52[0.29; 0.91]CASPIAN (D ; all population), 201910%531NAnot evaluable Arthritis TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.14; 7.18] 1.00[0.14; 7.18]CASPIAN (D ; all population), 201910%531NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.06; 16.13] 1.00[0.06; 16.13]CASPIAN (D ; all population), 201910%531NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 8.14 [0.43; 154.70] 8.14[0.43; 154.70]CASPIAN (D ; all population), 201910%531NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.14; 7.18] 1.00[0.14; 7.18]CASPIAN (D ; all population), 201910%531NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.67 [0.11; 4.02] 0.67[0.11; 4.02]CASPIAN (D ; all population), 201910%531NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.76 [0.36; 1.59] 0.76[0.36; 1.59]CASPIAN (D ; all population), 201910%531NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 8.25 [1.02; 66.42] 8.25[1.02; 66.42]CASPIAN (D ; all population), 201910%531NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.08 [0.51; 2.28] 1.08[0.51; 2.28]CASPIAN (D ; all population), 201910%531NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.10 [0.01; 1.82] 0.10[0.01; 1.82]CASPIAN (D ; all population), 201910%531NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.63 [0.43; 0.92] 0.63[0.43; 0.92]CASPIAN (D ; all population), 201910%531NAnot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 2.02 [0.18; 22.36] 2.02[0.18; 22.36]CASPIAN (D ; all population), 201910%531NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Rash TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.56 [0.28; 1.11] 0.56[0.28; 1.11]CASPIAN (D ; all population), 201910%531NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.25 [0.01; 5.56] 0.25[0.01; 5.56]CASPIAN (D ; all population), 201910%531NAnot evaluable Alopecia AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.51 [0.25; 9.12] 1.51[0.25; 9.12]CASPIAN (D ; all population), 201910%531NAnot evaluable Anaemia AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.45 [0.27; 0.76] 0.45[0.27; 0.76]CASPIAN (D ; all population), 201910%531NAnot evaluable Asthenia AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.69 [0.40; 7.13] 1.69[0.40; 7.13]CASPIAN (D ; all population), 201910%531NAnot evaluable Back pain AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 2.02 [0.18; 22.36] 2.02[0.18; 22.36]CASPIAN (D ; all population), 201910%531NAnot evaluable Constipation AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 4.04 [0.18; 89.97] 4.04[0.18; 89.97]CASPIAN (D ; all population), 201910%531NAnot evaluable Cough AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 4.04 [0.18; 89.97] 4.04[0.18; 89.97]CASPIAN (D ; all population), 201910%531NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.14; 7.18] 1.00[0.14; 7.18]CASPIAN (D ; all population), 201910%531NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.20; 5.02] 1.00[0.20; 5.02]CASPIAN (D ; all population), 201910%531NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.69 [0.40; 7.13] 1.69[0.40; 7.13]CASPIAN (D ; all population), 201910%531NAnot evaluable Fatigue AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.34 [0.30; 6.06] 1.34[0.30; 6.06]CASPIAN (D ; all population), 201910%531NAnot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.82 [0.39; 1.69] 0.82[0.39; 1.69]CASPIAN (D ; all population), 201910%531NAnot evaluable Headache AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 2.01 [0.07; 60.21] 2.01[0.07; 60.21]CASPIAN (D ; all population), 201910%531NAnot evaluable Hypertension AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 8.25 [1.02; 66.42] 8.25[1.02; 66.42]CASPIAN (D ; all population), 201910%531NAnot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Increased Lipase Level AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 2.30 [0.70; 7.57] 2.30[0.70; 7.57]CASPIAN (D ; all population), 201910%531NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.23 [0.60; 2.56] 1.23[0.60; 2.56]CASPIAN (D ; all population), 201910%531NAnot evaluable Nausea AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.20 [0.02; 1.70] 0.20[0.02; 1.70]CASPIAN (D ; all population), 201910%531NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.64 [0.44; 0.94] 0.64[0.44; 0.94]CASPIAN (D ; all population), 201910%531NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.55 [0.18; 1.66] 0.55[0.18; 1.66]CASPIAN (D ; all population), 201910%531NAnot evaluable Pruritus AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.50 [0.02; 15.00] 0.50[0.02; 15.00]CASPIAN (D ; all population), 201910%531NAnot evaluable Rash AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 1.00 [0.02; 50.78] 1.00[0.02; 50.78]CASPIAN (D ; all population), 201910%531NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.58 [0.30; 1.12] 0.58[0.30; 1.12]CASPIAN (D ; all population), 201910%531NAnot evaluable Vomiting AE (grade 3-4)detailed resultsCASPIAN (D ; all population), 2019 0.17 [0.01; 3.32] 0.17[0.01; 3.32]CASPIAN (D ; all population), 201910%531NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-11-01 02:01 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 281,194,162,172 - treatments: 1080

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons